Loading clinical trials...
Loading clinical trials...
Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Conditions
Interventions
BAY 59-7939
BAY 59-7939
+1 more
Locations
266
United States
Beverly Hills, California, United States
La Jolla, California, United States
Ventura, California, United States
Denver, Colorado, United States
Jacksonville, Florida, United States
Columbus, Georgia, United States
Start Date
March 5, 2014
Primary Completion Date
September 22, 2016
Completion Date
November 4, 2016
Last Updated
December 19, 2017
NCT06820515
NCT05969496
NCT06183944
NCT07410117
NCT06113510
NCT06189313
Lead Sponsor
Bayer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions